ES-31 78 REV. 1 /81 
ESTABLISHED 1802 
E. I. du Pont de Nemours & Company 
INCORPORATED 
Wilmington, Delaware 19898 
CENTRAL RESEARCH 8c DEVELOPMENT DEPARTMENT 
EXPERIMENTAL STATION 
January 20, 1983 
Dr. William J. Gartland 
Director of ORDA 
National Institutes of Health 
Building 31, Room 4A52 
Bethesda, Maryland 20205 
Dear Dr. Gartland: 
Dr. H. E. Simmons, Chairman of the Du Pont Institutional 
Biosafety Committee has asked me to respond to your memorandum 
requesting comments on the revised Guidelines for research 
involving recombinant DNA molecules. 
• We have encountered no problems with the revised Guidelines. 
• No matters that have come before our IBC have taken large or 
inappropriate amounts of time. 
• We have no disagreement with the RAC with regard to containment 
• We have no recommendations at this time for changes in the 
Guidelines . 
• Almost all the recombinant DNA research done on Du Pont sites 
under the surveillance of the IBC is exempt from the Guidelines 
We met twice in 1982. 
• Our IBC has responsibility for research covered by the guide- 
lines but monitors all recombinant DNA research on Du Pont 
sites under its jurisdiction. Individual sites have Du Pont 
guidelines and Biosafety committees to regulate and monitor 
other biological research. This organization is based 
primarily on corporate choice. 
Yours sincerely, 
C. Cameron McDonald 
Vice President, IBC 
CCM : ldks 
[581] 
